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Long-term and recent trends in hypertension awareness, 
treatment, and control in 12 high-income countries: 
an analysis of 123 nationally representative surveys
NCD Risk Factor Collaboration (NCD-RisC)*
Summary
Background Antihypertensive medicines are effective in reducing adverse cardiovascular events. Our aim was 
to compare hypertension awareness, treatment, and control, and how they have changed over time, in high-
income countries.
Methods We used data from people aged 40–79 years who participated in 123 national health examination surveys 
from 1976 to 2017 in 12 high-income countries: Australia, Canada, Finland, Germany, Ireland, Italy, Japan, 
New Zealand, South Korea, Spain, the UK, and the USA. We calculated the proportion of participants with 
hypertension, which was defined as systolic blood pressure of 140 mm Hg or more, or diastolic blood pressure of 
90 mm Hg or more, or being on pharmacological treatment for hypertension, who were aware of their condition, who 
were treated, and whose hypertension was controlled (ie, lower than 140/90 mm Hg).
Findings Data from 526 336 participants were used in these analyses. In their most recent surveys, Canada, 
South Korea, Australia, and the UK had the lowest prevalence of hypertension, and Finland the highest. In the 1980s 
and early 1990s, treatment rates were at most 40% and control rates were less than 25% in most countries and age 
and sex groups. Over the time period assessed, hypertension awareness and treatment increased and control rate 
improved in all 12 countries, with South Korea and Germany experiencing the largest improvements. Most of the 
observed increase occurred in the 1990s and early-mid 2000s, having plateaued since in most countries. In their most 
recent surveys, Canada, Germany, South Korea, and the USA had the highest rates of awareness, treatment, and 
control, whereas Finland, Ireland, Japan, and Spain had the lowest. Even in the best performing countries, treatment 
coverage was at most 80% and control rates were less than 70%.
Interpretation Hypertension awareness, treatment, and control have improved substantially in high-income countries 
since the 1980s and 1990s. However, control rates have plateaued in the past decade, at levels lower than those in high-
quality hypertension programmes. There is substantial variation across countries in the rates of hypertension 
awareness, treatment, and control.
Funding Wellcome Trust and WHO.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
High blood pressure is one of the most important risk 
factors for stroke, heart disease, and kidney disease.1 
Antihypertensive medicines can effectively reduce blood 
pressure and the risk of associated diseases.2,3 As clinical 
trials have shown the benefits of pharmacological 
treatment for patients with low to moderate blood 
pressure, clinical guidelines have evolved to recommend 
lower blood pressure thresholds for initiating treat­
ment. National and regional hypertension programmes 
(eg, the Canadian Hypertension Education Program and 
Kaiser Permanente Northern California hypertension 
programme4,5) have demonstrated that it is feasible to 
achieve a high level of hypertension control by improving 
health­care provider and patient compliance with 
evidence­based guidelines, establishing a hyper tension 
registry, monitoring physician performance and pro­
viding feedback, and implementing regular blood 
pressure measurements and single­pill combination 
therapy.4
There are, however, few data on how different high­
income countries, with different health systems and 
clinical guidelines, compare in terms of hypertension 
awareness, treatment, and control; how comparative 
performance in these countries has changed over time; 
and which countries need to improve hypertension 
management. We aimed to benchmark hypertension 
awareness, treatment, and control across 12 high­income 
countries over a period of nearly four decades using 
national data.
Methods
Data sources
In this analysis, we used data from 123 national health 
examination surveys that were done from 1976 to 2017 in 
12 high­income countries: Australia, Canada, Finland, 
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Germany, Ireland, Italy, Japan, New Zealand, South Korea, 
Spain, the UK, and the USA. These surveys measured 
blood pressure in random samples of the general 
population. A list of surveys used and information about 
their study designs, including age range and number of 
participants, number of blood pressure measurements 
taken, cuff size, and type of device used to measure blood 
pressure, are provided in the appendix (pp 3–6).
We used data on men and women aged 40–79 years. 
We did not use data on participants younger than 40 years 
because hypertension is less common in these ages. We 
did not use data on participants older than 80 years 
because guidelines recommend different treatment 
pathways and goals in older ages.
Data analysis
All analyses were done by sex and 10­year age groups. In 
surveys that covered only a part of the 10­year age group, 
we used the data only when the age range was 5 years 
or more; this criterion led to exclusion of data on 
220 participants (<0·1%). In each survey, we identified 
the question used to establish whether a participant had 
been diagnosed with hypertension, often worded as a 
variation of: “have you ever been told by a doctor or other 
health professional that you had hypertension, also 
called high blood pressure?” We did not consider having 
had hypertension diagnosis only during pregnancy as a 
previous diagnosis. We established whether participants 
had been pharmacologically treated for hypertension 
using survey­specific questions, which were typically 
worded in the following way: “Because of your 
hypertension, have you ever been told to take prescribed 
medicine? Are you now taking it?” “Are you currently 
taking any medicines, tablets or pills for high blood 
pressure?” We took a similar approach in surveys that 
had gathered information on medicines prescribed to 
the participants, by relying on survey information about 
hypertension being the purpose or diagnosis leading to 
taking a blood­pressure­lowering medicine. Participants 
with missing data on blood pressure, diagnosis, or 
treatment were excluded from the analysis (2% of data). 
After exclusion, we had data on 526 336 participants.
In each survey, we calculated the prevalence, and its 
95% CI, of hypertension, which was defined as systolic 
blood pressure of 140 mm Hg or more, or diastolic 
blood pressure of 90 mm Hg or more, or being on 
pharmacological treatment for hypertension. We also 
calculated the pro portion of participants with hypertension 
Research in context
Evidence before this study
We searched MEDLINE (via PubMed) for articles published 
from inception to Jan 15, 2019, using the search terms 
((hypertension[Title] AND (((medication OR treatment) AND 
control) OR aware*) AND “blood pressure”) OR 
(cardiovascular[Title] AND risk factor*[Title] AND “blood 
pressure” AND (((medication OR treatment) AND control) OR 
aware*))) AND (trend* OR global OR worldwide) NOT 
patient*[Title]. No language restrictions were applied. We 
found some studies on trends in hypertension prevalence, 
awareness, treatment, and control in individual countries. 
Only three of these studies, in the USA and South Korea, used 
post-2010 data and reported a plateau in hypertension 
treatment and control. We found a few studies or reviews 
that compared hypertension awareness, treatment, and 
control across countries at one point in time, mostly using 
data collected from the 1980s to the 2000s. These studies 
mostly compared high-income countries as a group with 
low-income and middle-income countries, and they did not 
assess change over time. One study reported change in 
hypertension prevalence, awareness, treatment, and control 
in 21 countries using subnational data from the MONICA 
Project between two points in time (late 1980s and early 
1990s). Another study, a systematic review of published 
studies, reported hypertension prevalence, awareness, 
treatment, and control in two points in time (2000 and 
2010). Both of these studies did not examine trends over time 
in detail and did not use data collected after 2010. To our 
knowledge, there are no comparative studies of long-term 
and recent trends in hypertension awareness, treatment, 
and control in high-income countries.
Added value of this study
This study provides the most comprehensive analysis of trends 
in hypertension awareness, treatment, and control in 
high-income countries using national surveys. By covering a 
substantially longer time period than previous studies, we 
noted not only substantial improvements in hypertension 
awareness, treatment, and control since hypertension 
treatment was incorporated in clinical guidelines, but also 
variations in the uptake of treatment and success of control 
across countries. By use of up-to-date national surveys in each 
country, we could evaluate recent trends, which revealed a 
plateau of the improvements in hypertension treatment 
coverage and control in most countries.
Implications of all the available evidence
There has been substantial improvement in hypertension 
awareness, treatment, and control in high-income countries 
since the 1980s and 1990s, most of which was achieved in the 
late 1990s and early 2000s. Canada, Germany, South Korea, 
and the USA have the highest rates of awareness, treatment, 
and control, whereas Finland, Ireland, Japan, and Spain have the 
lowest. Even in the best performing countries, the rates fall 
short of those achieved in high-quality hypertension 
programmes—eg, the Kaiser Permanente Northern California 
hypertension programme. There is need for strategies that 
further improve the diagnosis, treatment, and control of 
hypertension in high-income countries.
See Online for appendix
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who reported having been diagnosed (awareness), who 
were using medication to treat hypertension (treatment), 
and who had systolic blood pressure of less than 140 mm Hg 
and diastolic blood pressure of less than 90 mm Hg 
(control). Blood pressure of each participant was measured 
more than once in all surveys, except those in Japan before 
2000. When more than one measurement was taken, we 
discarded the first and used the remainder for the 
aforementioned analyses, by averaging when more 
than two measurements were taken. 37 surveys with 
175 437 participants had data on hypertension treatment but 
not on diagnosis. 27 of these surveys were from Japan, 
which in its annual national survey asks questions about 
treatment every year but about diagnosis every 10 years. For 
these surveys, we calculated hypertension prevalence, 
treatment, and control, but not awareness. Where relevant, 
we accounted for complex survey design and used survey 
sample weights when calculating prevalence, awareness, 
treatment, and control.
Immediate pharmacological treatment is recommended 
for people with stage 2 hypertension (ie, systolic blood 
pressure of 160 mm Hg or more, or diastolic blood 
pressure of 100 mm Hg or more) by all hypertension 
guidelines, and failure to provide such treatment is a 
Figure 1: Trends in hypertension prevalence by country, sex, and age group
See appendix (pp 29–41) for country-by-country results. Error bars indicate 95% CIs.
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shortcoming in the health­care system. Therefore, we also 
calculated the proportion of people with hypertension who 
had stage 2 hypertension but were unaware of or untreated 
for their condition.
Role of the funding source
The funder of the study had no role in study design, data 
collection, analysis, interpretation, or writing of the 
report. BZ had full access to the data in the study. 
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(Figure 3 continues on next page)
Women Men 
Prevalence Awareness Treatment Control  Prevalence Awareness Treatment Control  
Australia (2012) 33% 75% 65% 38% 39% 67% 55% 28% 
Canada (2016–17) 36% 72% 66% 50% 34% 84% 81% 69% 
Finland (2017) 52% 77% 59% 29% 59% 74% 55% 26% 
Germany (2008–11) 43% 87% 80% 58% 46% 82% 70% 48% 
Ireland (2009–11)* 43% 56% 50% 26% 56% 46% 39% 17% 
Italy (2008–12) 45% 77% 68% 31% 56% 69% 56% 23% 
Japan (2015) 40% 66%†  55% 29% 56% 65%†  52% 24% 
New Zealand (2015–16) 41% 75% 62% 35% 45% 69% 55% 28% 
South Korea (2016) 34% 76% 74% 53% 44% 68% 65% 46% 
Spain (2015)‡ 36% 69% 56% 29% 53% 64% 51% 25% 
UK (2016) 36% 70% 59% 37% 40% 67% 55% 37% 
USA (2015–16) 44% 86% 80% 54% 45% 79% 70% 49% 
Figure 2: Prevalence of hypertension and rates of awareness, treatment, and 
control in women and men aged 40–79 years
Data are from the latest national survey in each country. Results shown are crude 
(ie, not age-standardised) to reflect the total burden of hypertension and its 
awareness, treatment, and control. Age-specific results, and their uncertainty, 
are available in figures 1 and 3–6, and the appendix (pp 7–9). For each outcome, 
the colour range for cells extends from lowest to highest value. Men and women 
share the same colour scheme. Awareness, treatment, and control are reported 
as the proportions. *The latest national survey in Ireland had data for people 
aged 50 to 79 years; data from an earlier survey in 2007 were used for people 
aged 40 to 49 years. †The question on awareness was not asked in 2015 in 
Japan; awareness data from 2010 were used. ‡The latest national survey in Spain 
had data for people aged 60 to 79 years; data from an earlier survey in 2009 
were used for people aged 40 to 59 years.
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The corresponding author had final responsibility for the 
decision to submit for publication.
Results
In the most recent national surveys, Canada, 
South Korea, Australia, and the UK had the lowest 
prevalence of hypertension, and Finland the highest 
(figures 1, 2). Prevalence was also higher than 50% in 
men in Ireland, Italy, Japan, and Spain. In ages 
40–49 years, hypertension prevalence ranged from 12% 
(95% CI 9–15; South Korea) to 20% (17–24; Finland) 
in women, and from 10% (4–16; Canada) to 37% 
(33–42; Finland) in men. In ages 70–79 years, 
prevalence ranged from 61% (49–72; Canada) to 82% 
(79–86; Finland) in women, and from 55% (45–65; USA) 
to 77% (74–80; Italy) in men (figure 1; appendix pp 7–9). 
Overall prevalence across all participants aged 
40–79 years ranged from 33% in Australia to 52% in 
Finland in women, and from 34% in Canada to 59% in 
Finland in men (figure 2).
In most countries and among age and sex groups, 
hypertension prevalence did not change over time, 
although some age and sex groups showed a decline, 
especially after the mid­2000s (figure 1; see appendix p 10 
for p values for change since 2005). The only group in 
which hypertension prevalence increased was 
South Korean men and women aged 70–79 years.
Awareness and treatment of hypertension increased in 
most countries (figure 3). Much of the improvement 
happened before the mid­2000s, and awareness and 
treatment have plateaued since, at levels between 40% 
and 80% depending on age (figure 3; see appendix 
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Figure 3: Trends in hypertension awareness and treatment among people with hypertension, by country, sex, and age group
See appendix (pp 29–41) for country-by-country results. Error bars indicate 95% CIs.
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pp 11–12 for p values for change since 2005). Awareness 
and treatment rates were lower in younger age groups 
than in older ones (figure 4).
The USA started with higher rates of awareness (about 
50% or more in different age groups) and treatment 
(about 25% or more in different age groups) than other 
countries in the 1980s and 1990s, and has largely 
maintained this advantage (figures 2, 3). In their most 
recent surveys, Canada, Germany, and South Korea also 
had high rates of hypertension awareness and treatment, 
in some age and sex groups having surpassed the USA. 
The USA, Canada, and Germany not only had high 
awareness and treatment rates, but also a smaller age 
gradient in awareness and treatment (figure 4), meaning 
that diagnosis and treatment are benefiting all ages. 
Australia, which had similar rates of awareness and 
treatment to the USA in the 1990s, has fallen behind, 
with awareness and treatment for men now in the lower 
half of these 12 countries (figure 2). By contrast, 
South Korea and the UK started with relatively low 
rates of hypertension awareness and treatment, but 
have closed the gap with (the UK) or outperformed 
(South Korea) most other countries because of a sharp 
increase in the late 1990s and early 2000s. There might, 
however, have been a slight decrease in hypertension 
awareness and treatment in the UK and in Canadian 
Figure 4: Age patterns of hypertension awareness, treatment, and control among women and men, according to the latest national surveys
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women in the past 5 years (appendix pp 31, 40), which 
needs to be confirmed when additional years of data 
become available. Finally, although hypertension 
awareness and treatment increased in Japan at a steady 
pace since the 1980s, it remains lower than in most 
other countries.
As awareness and treatment rates increased, the 
proportion of people with hypertension who had stage 2 
hypertension but were not diagnosed or treated declined 
markedly, especially in older ages (figure 5). In the latest 
surveys, this proportion was less than 5% in most age 
groups in Germany and the USA and in older age groups 
in South Korea. By contrast, in some age and sex 
groups in Finland, Italy, Japan, and New Zealand, 
15–25% of participants with hypertension had untreated 
stage 2 hypertension.
In the 1980s and early 1990s, the proportion of people 
with hypertension whose hypertension was controlled 
(ie, had achieved systolic blood pressure of less than 
140 mm Hg and diastolic blood pressure of less than 
90 mm Hg) was less than 25% in most countries and age 
and sex groups (figure 6). Control rates improved over 
time, reaching 60–70% in some countries and age and 
sex groups. Like awareness and treatment rates, this 
increase mostly happened in the 1990s and early­mid 
2000s, with slower improvement since then followed by a 
plateau after the mid­2000s in most countries and age 
groups (see appendix p 13 for p values for change since 
2005). Even in countries with the highest rates of 
control—namely, Canada, South Korea, the USA, and 
Germany—the plateau occurred below 70% when taken 
across the entire 40–79­year age range (figure 2). 
Hypertension control was lower in Finland, Ireland, 
Italy, Japan, and Spain than in other countries, with 
control rates being less than 20% in some age and sex 
groups. Taken across the entire 40–79 years, control rates 
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in Canada and Germany (50–58% for women and 
48–69% for men) were two to four times those in Ireland, 
Japan, Italy, Spain, and Finland (26–31% for women and 
17–26% for men). Suboptimal control was partly because 
some people with hypertension were not treated, and 
partly because control rate among those treated was at 
most around 80% (figure 6).
Discussion
By use of data on more than 520 000 participants in 
123 national health examination surveys from 12 high­
income countries, we found that hypertension awareness, 
treatment, and control have improved substantially in all 
12 countries since the 1980s and 1990s. However, control 
rates have plateaued in the past decade, at levels lower 
than those in high­quality hypertension programmes, 
such as the Kaiser Permanente Northern California 
hypertension programme.4 Suboptimal control occurs 
partly because some people with hypertension, even with 
stage 2 hypertension, are not diagnosed or treated, and 
partly because at least 20% of those diagnosed and treated 
fail to achieve control. There were nonetheless variations 
across countries in both hypertension prevalence and 
how health systems detect and treat hypertension. 
Although the USA consistently performed better than 
most of its comparators in terms of awareness, treatment, 
and control, Canada, Germany, and South Korea have 
achieved substantial improvements and now perform as 
well as, or better than, the USA. Finland, Japan, Ireland, 
Italy, Spain, and men in New Zealand had lower rates of 
awareness, treatment, and control than most other 
countries assessed.
To our knowledge, there are no multinational studies 
comparing trends in hypertension awareness, treatment, 
Figure 5: Trends in proportion of people with hypertension who had undiagnosed or untreated stage 2 hypertension, by country, sex, and age group
Error bars indicate 95% CIs.
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and control in high­income countries. A few cross­
sectional studies or reviews compared prevalence, 
awareness, treatment, and control using national or 
subnational data mostly between the 1980s and 2000s.6–14 
These studies mostly compared high­income countries 
as a group with low­income and middle­income countries 
and did not examine variations among high­income 
countries. Change over time has been reported primarily 
in individual countries, with the exception of the 
MONICA study,7 which reported change from the mid­
1980s to the mid­1990s using subnational data, and a 
systematic review of published studies9 that reported on 
hypertension for two points in time (2000 and 2010). 
These studies did not examine trends over time in detail, 
including the rapid increase in diagnosis and treatment 
in the late 1990s and early 2000s, and they did not find 
the recent plateau as we reported here because they did 
not have data after 2010. The findings of these studies on 
countries with better (eg, Canada and the USA) and 
worse (eg, the UK) performance were largely consistent 
with ours.7–11 Only two studies from the USA15,16 and one 
from South Korea17 reported a plateau in hypertension 
treatment and control, as we reported here, because 
previous studies used fewer and older data sources, 
largely before 2010. Given the large variation across these 
12 countries in the rates of awareness, treatment, and 
control, understanding health system performance in 
hypertension treatment in other high­income countries 
requires local data.
The strengths of our study include its scope of 
comparative analysis in 12 countries over around four 
decades, which allowed trends, including accelerations 
and plateau, and variations across countries, to be 
uncovered, and the large number of high­quality 
national surveys used in the analysis. A limitation of 
data was that fewer surveys were available before 1990, 
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which restricted comparisons in the early part of the 
analysis period. Some surveys did not have data on 
hypertension diagnosis; nonetheless, countries with 
such features (eg, Japan) still had sufficient data to 
evaluate trends in awareness. Furthermore, survey 
protocols might differ across countries because of 
differences in their geographical and social circum­
stances. For example, the time before blood pressure is 
measured might differ across surveys. Nonetheless, 
surveys commonly start with an interview module before 
moving to physical measurements, which allows 
sufficient time for stabilisation of blood pressure, and all 
survey protocols include a resting time before blood 
pressure measurement.18 Finally, over time, standard 
mercury sphygmomanometers have been replaced by 
random­zero sphygmomanometers and, more recently, 
digital oscillometric devices in some health surveys. 
Surveys used in our study used the same type of device 
over time in each country, except those in Australia, 
Canada, Germany, and Spain, where the measurement 
instrument used changed over time (appendix pp 4–6). 
The effect of measurement device on hypertension 
prevalence depends on the circumstances of each survey. 
For example, an automated digital device, although not 
the traditional gold standard in a clinical setting, might 
help to reduce potential observer bias, compared with a 
standard mercury sphygmomanometer.19 However, 
measurements from different devices might not be fully 
comparable.20
The increase in hypertension awareness, treatment, 
and control, especially in the 1990s and early 2000s, 
was probably due to more widespread uptake of, 
and compliance with, clinical guidelines for hyper­
tension with simplified recommendations (see appendix 
Figure 6: Trends in hypertension control, by country, sex, and age group
See appendix (pp 29–41) for country-by-country results. Error bars indicate 95% CIs. 
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pp 14–24 for details on national and international 
guidelines). The progressively lower thresholds to 
diagnose hypertension and initiate treatment also 
contributed to higher rates of awareness, treatment, and 
control based on the threshold of 140/90 mm Hg. Over 
time, newer drugs became available (eg, renin–
angiotensin system inhibitors and calcium­channel 
blockers),21 and improved treatment efficacy and control 
for some patients and had smaller side­effects than 
did the older generation ones (eg, thiazide diuretics).22 
Because multiple agents are usually needed to achieve 
blood pressure targets, the use of fixed­dose combi­
nation therapy is likely to have reduced medication 
regimen complexity and improved treatment adherence 
and control.23 Nationally implemented screening 
and health check­up programmes (eg, in Canada24 and 
South Korea25), and tighter control targets might also 
have contributed to the observed improvements.
Low rates of awareness, treatment, and control in some 
countries might be partly related to higher thresholds for 
pharmacological treatment in clinical guidelines for 
hypertension. For example, in Finland, which had one of 
the lowest rates of treatment and control, the threshold 
for treatment was only recently lowered to 140/90 mm Hg 
(appendix p 17).26 Guidelines also differ in their 
recommendations for patients with blood pressure 
between 140/90 mm Hg and 160/100 mm Hg and with 
low levels of other risk factors (appendix pp 14–24). Some 
recommend immediate treatment,24,27 others recommend 
starting with lifestyle changes before initiating 
treatment,28,29 and yet others do not make an explicit 
recommendation for this group.30–32 As a result, physicians 
in some countries are less likely to treat patients 
with blood pressure between 140/90 mm Hg and 
160/100 mm Hg than in other countries—eg, Japan 
compared with the USA.33,34 The extent of reliance on total 
cardiovascular risk versus blood pressure might also 
contribute to the observed variation in treatment across 
countries. In particular, New Zealand, which had below 
average treatment coverage in our study, has stopped 
publishing dedicated clinical guidelines for hypertension 
and relies on total cardiovascular risk for treatment 
decisions except for stage 2 hypertension.32 Beyond 
guidelines, health system characteristics that facilitate or 
impede contact with providers, including insurance, co­
payment for physician consultation or prescription, and 
pay­for­performance incentives to physicians, might 
affect how often people see their physicians and have 
their blood pressure measured, whether antihypertensive 
medicines are prescribed, and whether patients comply 
with the treatment (see appendix pp 25–28 for information 
on health systems in these 12 countries). In addition to 
these systems determinants, the countries with the 
best hypertension control—ie, Canada, the USA, South 
Korea, and Germany—all have national programmes for 
hypertension education or health check­up (appendix 
pp 25–28). Detailed evaluation of the Canadian 
Hypertension Education Program shows that annual 
update of recommendations, tailored knowledge dis­
semination, coordinated implementation and outcome 
evaluation, and national leadership are also important for 
the success of national hypertension programmes.35
Randomised trials over half a century have shown the 
benefits of treating hypertension, at progressively lower 
thresholds and with multiple drugs. Our results show 
that when incorporated in guidelines and implemented 
in effective health systems, treatment coverage and 
control rates can rapidly increase. Yet even in these well 
resourced countries, treatment coverage and control 
vary substantially across countries, and rarely reach the 
levels achieved in high­quality regional hypertension 
programmes. The increasing use of fixed­dose combi­
nation therapy can help to increase control rates among 
treated patients.36 Increasing diagnosis and treatment, 
however, requires mechanisms and incentives that 
increase contact with health­care systems, especially 
for disadvantaged groups that typically have higher 
prevalence of hypertension and lower rates of diagnosis 
and treatment.37,38 National health systems should set 
ambitious targets, and experiment and rigorously 
evaluate innovative mechanisms at the facility and 
community levels4,38,39 to improve hypertension awareness, 
treatment, and control. Doing so would help to address 
the large burden of uncontrolled hypertension.40
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